Related Experiment Video
Updated: Jan 14, 2026
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
Bi-functional integrin degraders cause stronger anti-proliferative effects than a blocking antibody by modulating
Meghan F Monroy1,2, Megan Krumpoch3, T Andrew McTeague4
1Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA.
Abstract:
Integrins play a critical role in signaling events that regulate cell adhesion, migration, and proliferation, processes that, when dysregulated, contribute to cancer progression. Recently, innovative approaches that target extracellular proteins for degradation have suggested potential in cancer treatment by removing specific cell surface receptors and trafficking them to the lysosome for breakdown. In this context, two integrin degraders were engineered, each exploiting different lysosomal targeting pathways: the asialoglycoprotein receptor (ASGPR) and zinc and ring finger 3 (ZNRF3), respectively. Both degraders use a pan-selective human αv antibody that fully blocks ligand binding, effectively internalizing and degrading αv integrins in vitro and in vivo. Degrading cell-surface αv integrins, rather than merely blocking their interactions with the extracellular matrix (ECM), produces a stronger anti-proliferative effect by more robustly modulating oncogenic signaling pathways. Notably, these degraders exploit distinct mechanisms, including the first reporting of more profound changes in tumor-promoting integrin signaling cascades compared to ligand blocking alone, highlighting a novel avenue for integrin-targeted drug development. This strategy leads to greater suppression of tumor cell growth making it a promising and potentially superior approach to cancer therapy. Similar to other reports, in vivo efficacy has yet to be shown with extracellular or membrane-targeted protein degraders. Through careful pharmacokinetics characterizations, we showed that lack of in vivo efficacy may be due to insufficient exposure and target engagement. Our study provides useful lessons for the field to fully realize the full potential for the next generation of degrader therapeutics.
Insights
Engineered integrin degraders targeting cell surface receptors show enhanced anti-cancer effects by promoting degradation over blocking. This novel approach offers a promising strategy for cancer therapy, though in vivo efficacy requires further investigation.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Integrins are crucial for cell functions like adhesion and migration, and their dysregulation drives cancer progression.
- Targeting extracellular proteins for degradation offers a novel cancer treatment strategy by removing cell surface receptors.
- Two integrin degraders were engineered utilizing distinct lysosomal targeting pathways: asialoglycoprotein receptor (ASGPR) and zinc and ring finger 3 (ZNRF3).
Purpose of the Study:
- To engineer and evaluate novel integrin degraders for cancer therapy.
- To compare the efficacy of integrin degradation versus ligand blocking in modulating oncogenic signaling.
- To investigate the in vivo pharmacokinetics and target engagement of these novel degraders.
Main Methods:
- Engineered degraders employing a pan-selective human αv antibody to target and internalize αv integrins.
- Evaluated integrin degradation and anti-proliferative effects in vitro and in vivo.
- Conducted pharmacokinetic characterizations to assess in vivo exposure and target engagement.
Main Results:
- Both engineered degraders effectively internalized and degraded αv integrins in vitro and in vivo.
- Degrading cell-surface αv integrins demonstrated a stronger anti-proliferative effect compared to ligand blocking alone.
- Observed profound changes in tumor-promoting integrin signaling cascades, exceeding those from ligand blocking.
- Identified insufficient exposure and target engagement as potential limitations for in vivo efficacy.
Conclusions:
- Integrin degradation represents a promising and potentially superior approach to cancer therapy compared to ligand blocking.
- The study highlights a novel avenue for integrin-targeted drug development with enhanced suppression of tumor cell growth.
- Further research is needed to optimize pharmacokinetics for successful in vivo application of extracellular protein degraders.
More Related Videos
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:15Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
01:16TGF - β Signaling Pathway
01:10Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...